Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli over a 6-year period

J Korean Med Sci. 2013 Jul;28(7):998-1004. doi: 10.3346/jkms.2013.28.7.998. Epub 2013 Jul 3.

Abstract

Although extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) has emerged as a significant community-acquired pathogen, there is little epidemiological information regarding community-onset bacteremia due to ESBL-EC. A retrospective observational study from 2006 through 2011 was performed to evaluate the epidemiology of community-onset bacteremia caused by ESBL-EC. In a six-year period, the proportion of ESBL-EC responsible for causing community-onset bacteremia had increased significantly, from 3.6% in 2006 to 14.3%, in 2011. Of the 97 clinically evaluable cases with ESBL-EC bacteremia, 32 (33.0%) were further classified as healthcare-associated infections. The most common site of infection was urinary tract infection (n=35, 36.1%), followed by biliary tract infections (n=29, 29.9%). Of the 103 ESBL-EC isolates, 43 (41.7%) produced CTX-M-14 and 36 (35.0%) produced CTX-M-15. In the multilocus sequence typing (MLST) analysis of 76 isolates with CTX-M-14 or -15 type ESBLs, the most prevalent sequence type (ST) was ST131 (n=15, 19.7%), followed by ST405 (n=12, 15.8%) and ST648 (n=8, 10.5%). No significant differences in clinical features were found in the ST131 group versus the other group. These findings suggest that epidemic ESBL-EC clones such as CTX-M-14 or -15 type ESBLs and ST131 have disseminated in community-onset infections, even in bloodstream infections, which are the most serious type of infection.

Keywords: Bacteremia; Cephalosporin Resistance; Community-Acquired Infections; Epidemiology; Escherichia coli.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging
  • Bacteremia / drug therapy
  • Bacteremia / epidemiology*
  • Biliary Tract Diseases / epidemiology
  • Biliary Tract Diseases / microbiology
  • Cephalosporin Resistance / genetics
  • Cephalosporins / therapeutic use
  • Community-Acquired Infections / epidemiology*
  • Community-Acquired Infections / microbiology
  • Escherichia coli / isolation & purification
  • Escherichia coli / metabolism
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / epidemiology*
  • Female
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Molecular Epidemiology
  • Multilocus Sequence Typing
  • Prevalence
  • Retrospective Studies
  • Urinary Tract Infections / epidemiology
  • Urinary Tract Infections / microbiology
  • beta-Lactamases / metabolism*

Substances

  • Cephalosporins
  • beta-lactamase CTX-M-14
  • beta-lactamase CTX-M-15
  • beta-Lactamases